Patient P-02244
Therapy response
Declining
Tolerance
Stable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
82%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 No meaningful change — Dietary Support Protocol NP-02
- Day 62 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 71 GI-04 recommended — GI Support Protocol GI-04
- Day 72 Patient accepted — Started GI-04 in the companion
- Day 80 GI symptom burden −25% vs expected — GI Support Protocol GI-04
- Day 86 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 62.
Primary contributors, last 14 days
- GI instability+13
- Treatment adherence-11
- Inflammatory activity+7
- Nutritional resilience-5
- Toxicity-3
What helped?
- Dietary Support Protocol NP-02Day 47Result: no meaningful change
- GI Support Protocol GI-04Day 71Result: symptom burden −25%
LIFE OS recommendation
Monitoring Escalation ME-01
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 37/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 53
- WearableHRV 25 ms, trending down
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 43
- Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 53 and rising
- Autonomic recovery ↓45
- WearableResting HR 84 bpm
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 1.9 · butyrate capacity 37/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 26 ms
- Sleep
- 6.0 h
- Steps
- 5,176
- Resting HR
- 82 bpm
Daily log: GI score 53, nutritional resilience 46, adherence 49.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.